|
Video: What is a Stock Split?
|
|
Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TUKYSA®, or tucatinib, for the treatment of certain metastatic HER2-positive breast and colorectal cancers, and TIVDAK®, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. According to our SGEN stock split history records, SGEN has had 0 splits. | |
|
SGEN (SGEN) has 0 splits in our SGEN stock split history database.
Looking at the SGEN stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SGEN shares, starting with a $10,000 purchase of SGEN, presented on a split-history-adjusted basis factoring in the complete SGEN stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
12/13/2023 |
|
Start price/share: |
$40.87 |
|
End price/share: |
$228.74 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
459.68% |
|
Average Annual Total Return: |
19.54% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$55,969.29 |
|
Years: |
9.65 |
|
|
|
|
|